Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_2
2
67%
Ph phase_3
1
33%

Phase Distribution

0

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 22 (66.7%)
Phase 31 (33.3%)

Trials by Status

terminated133%
unknown267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI

NCT01812213
unknownphase_3

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

NCT01886820
unknownphase_2

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

NCT01680588

Clinical Trials (3)

Showing 3 of 3 trials
NCT01812213Phase 2

Beta-Amyloid Imaging With [18F]NAV4694 PET in Predicting Progression to AD in Subjects MCI

Terminated
NCT01886820Phase 3

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of [18F]NAV4694 PET for Detection of Cerebral Beta-Amyloid When Compared With Postmortem Histopathology

Unknown
NCT01680588Phase 2

Efficacy and Safety of the PET Imaging Agent [18F]NAV4694 in Subjects With Probable Alzheimer's Disease

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3